See more : Dimension Computer Technology Co., Ltd. (6140.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Merck & Co., Inc. (MRK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Merck & Co., Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Elos Medtech AB (publ) (ELOS-B.ST) Income Statement Analysis – Financial Results
- Mabuchi Motor Co., Ltd. (MBUMY) Income Statement Analysis – Financial Results
- The Boeing Company (BCO.DE) Income Statement Analysis – Financial Results
- APAC Resources Limited (APPCF) Income Statement Analysis – Financial Results
- Cyber Security Cloud , Inc. (4493.T) Income Statement Analysis – Financial Results
Merck & Co., Inc. (MRK)
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.12B | 59.28B | 48.70B | 41.52B | 46.84B | 42.29B | 40.12B | 39.81B | 39.50B | 42.24B | 44.03B | 47.27B | 48.05B | 45.99B | 27.43B | 23.85B | 24.20B | 22.64B | 22.01B | 22.94B | 22.49B | 51.79B | 47.72B | 40.36B | 32.71B | 26.90B | 23.64B | 19.83B | 16.68B | 14.97B | 10.50B | 9.66B | 8.60B | 7.67B | 6.55B | 5.94B | 5.06B | 4.13B | 3.55B |
| Cost of Revenue | 16.13B | 17.41B | 13.63B | 13.62B | 14.11B | 13.51B | 12.78B | 13.89B | 14.93B | 16.77B | 16.95B | 16.45B | 16.87B | 18.40B | 9.02B | 5.58B | 6.14B | 6.00B | 5.15B | 4.96B | 4.32B | 33.05B | 28.98B | 21.17B | 16.71B | 13.17B | 10.95B | 8.59B | 6.79B | 5.28B | 2.11B | 1.77B | 1.67B | 1.52B | 1.33B | 1.32B | 1.23B | 1.14B | 1.09B |
| Gross Profit | 43.99B | 41.87B | 35.08B | 27.90B | 32.73B | 28.79B | 27.35B | 25.92B | 24.56B | 25.47B | 27.08B | 30.82B | 31.18B | 27.59B | 18.41B | 18.27B | 18.06B | 16.63B | 16.86B | 17.98B | 18.17B | 18.74B | 18.74B | 19.20B | 16.01B | 13.72B | 12.68B | 11.24B | 9.89B | 9.69B | 8.39B | 7.89B | 6.93B | 6.15B | 5.22B | 4.62B | 3.83B | 2.98B | 2.46B |
| Gross Profit Ratio | 73.17% | 70.63% | 72.02% | 67.20% | 69.87% | 68.06% | 68.16% | 65.10% | 62.19% | 60.30% | 61.50% | 65.21% | 64.89% | 60.00% | 67.12% | 76.59% | 74.62% | 73.49% | 76.61% | 78.38% | 80.81% | 36.18% | 39.27% | 47.56% | 48.93% | 51.02% | 53.66% | 56.69% | 59.30% | 64.72% | 79.89% | 81.63% | 80.57% | 80.13% | 79.72% | 77.76% | 75.61% | 72.29% | 69.28% |
| Research & Development | 30.53B | 13.55B | 12.25B | 13.40B | 9.87B | 9.75B | 9.98B | 7.19B | 6.70B | 7.18B | 7.50B | 8.17B | 8.47B | 10.99B | 5.85B | 4.81B | 4.88B | 4.78B | 3.85B | 4.01B | 3.18B | 2.68B | 2.46B | 2.34B | 2.07B | 1.82B | 1.68B | 1.49B | 1.33B | 1.23B | 1.17B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.20B | 7.84B | 7.63B | 7.16B | 8.72B | 8.00B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.30B | 2.20B | 2.00B | 1.80B | 1.90B | 2.10B | 9.83B | 9.76B | 10.31B | 11.61B | 11.91B | 12.78B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.50B | 10.04B | 9.63B | 8.96B | 10.62B | 10.10B | 9.83B | 9.76B | 10.31B | 11.61B | 11.91B | 12.78B | 13.73B | 13.25B | 8.54B | 7.38B | 7.56B | 8.17B | 7.16B | 7.35B | 6.39B | 6.19B | 6.22B | 6.17B | 5.20B | 4.51B | 4.30B | 3.84B | 3.30B | 3.18B | 2.91B | 4.07B | 3.56B | 3.24B | 2.76B | 2.55B | 2.25B | 1.75B | 1.33B |
| Other Expenses | 0.00 | 960.00M | 468.00M | 469.00M | -139.00M | 849.00M | 304.00M | -357.00M | -72.00M | 12.00B | 12.00M | 44.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 40.91B | 23.59B | 21.88B | 22.35B | 20.49B | 19.85B | 19.81B | 16.96B | 17.02B | 18.79B | 19.41B | 20.94B | 22.20B | 24.24B | 14.39B | 12.18B | 12.44B | 12.95B | 11.00B | 11.36B | 9.71B | 9.07B | 9.01B | 10.11B | 8.41B | 7.35B | 7.02B | 6.26B | 5.49B | 5.28B | 4.50B | 4.40B | 3.82B | 3.50B | 2.99B | 2.75B | 2.46B | 1.94B | 1.62B |
| Cost & Expenses | 57.16B | 41.00B | 35.51B | 35.97B | 34.60B | 33.36B | 32.59B | 30.85B | 31.95B | 35.55B | 36.37B | 37.39B | 39.07B | 42.63B | 23.41B | 17.76B | 18.58B | 18.95B | 16.15B | 16.32B | 14.03B | 42.12B | 37.99B | 31.27B | 25.12B | 20.52B | 17.97B | 14.84B | 12.28B | 10.56B | 6.61B | 6.17B | 5.49B | 5.02B | 4.31B | 4.07B | 3.69B | 3.09B | 2.71B |
| Interest Income | 365.00M | 157.00M | 36.00M | 59.00M | 274.00M | 343.00M | 385.00M | 328.00M | 289.00M | 266.00M | 264.00M | 232.00M | 199.00M | 83.00M | 210.20M | 631.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.15B | 962.00M | 806.00M | 831.00M | 893.00M | 772.00M | 754.00M | 693.00M | 672.00M | 732.00M | 801.00M | 714.00M | 749.00M | 715.00M | 458.00M | 251.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.87B | 3.91B | 3.21B | 3.49B | 3.65B | 4.52B | 4.64B | 5.44B | 6.38B | 6.69B | 6.99B | 6.98B | 7.43B | 7.38B | 2.58B | 1.63B | 1.99B | 2.27B | 1.71B | 1.45B | 1.31B | 1.49B | 1.46B | 1.28B | 1.14B | 1.02B | 1.03B | 927.10M | 859.20M | 875.50M | 414.70M | 321.40M | 263.80M | 254.00M | 221.70M | 204.90M | 210.00M | 193.90M | 182.50M |
| EBITDA | 6.91B | 21.32B | 17.90B | 10.18B | 16.01B | 13.99B | 11.95B | 10.79B | 12.45B | 24.71B | 13.33B | 16.43B | 15.51B | 9.75B | 18.33B | 11.81B | 13.06B | 5.98B | 7.75B | 7.58B | 9.44B | 11.07B | 10.94B | 9.63B | 7.54B | 5.27B | 5.64B | 5.07B | 4.68B | 5.05B | 4.95B | 3.74B | 3.32B | 2.86B | 2.41B | 2.07B | 1.54B | 1.13B | 936.90M |
| EBITDA Ratio | 11.49% | 39.32% | 34.73% | 23.03% | 27.50% | 24.24% | 20.60% | 22.65% | 20.18% | 45.48% | 18.95% | 22.84% | 20.37% | 24.80% | -18.28% | 28.56% | 53.99% | 26.43% | 35.22% | 33.05% | 41.98% | 21.37% | 22.92% | 23.85% | 23.05% | 19.58% | 23.88% | 25.58% | 28.05% | 33.75% | 47.14% | 38.71% | 38.55% | 37.25% | 36.81% | 34.81% | 30.49% | 27.47% | 26.41% |
| Operating Income | 2.95B | 19.40B | 13.70B | 6.08B | 9.23B | 5.73B | 3.63B | 3.58B | 1.59B | 12.52B | 1.36B | 3.82B | 2.36B | 4.03B | -7.59B | 5.18B | 11.08B | 3.71B | 6.04B | 6.13B | 8.13B | 9.58B | 9.47B | 8.35B | 6.39B | 4.25B | 4.61B | 4.15B | 3.82B | 4.18B | 4.53B | 3.42B | 3.05B | 2.60B | 2.19B | 1.86B | 1.33B | 940.20M | 754.40M |
| Operating Income Ratio | 4.91% | 32.72% | 28.14% | 14.63% | 19.70% | 13.55% | 9.04% | 8.98% | 4.04% | 29.64% | 3.08% | 8.08% | 4.91% | 8.75% | -27.67% | 21.72% | 45.77% | 16.41% | 27.46% | 26.73% | 36.14% | 18.50% | 19.86% | 20.69% | 19.55% | 15.80% | 19.50% | 20.91% | 22.90% | 27.90% | 43.19% | 35.39% | 35.49% | 33.94% | 33.43% | 31.36% | 26.34% | 22.77% | 21.27% |
| Total Other Income/Expenses | -1.07B | -1.84B | 680.00M | 315.00M | 3.54B | -230.00M | -986.00M | 1.08B | -2.15B | 4.77B | -2.12B | -1.14B | -1.64B | -1.70B | 11.27B | 3.85B | -2.25B | 2.63B | 1.44B | 530.90M | 926.30M | 632.60M | 927.90M | 735.00M | 2.23B | 3.88B | 1.85B | 1.40B | 977.80M | 238.00M | -783.00M | 144.20M | 114.00M | 94.80M | 93.40M | 8.40M | 72.00M | 133.10M | 102.60M |
| Income Before Tax | 1.89B | 16.44B | 13.88B | 8.79B | 11.46B | 8.70B | 6.75B | 7.50B | 5.40B | 17.28B | 5.55B | 9.23B | 7.33B | 1.65B | 15.29B | 9.81B | 3.37B | 6.22B | 7.36B | 7.97B | 9.05B | 10.21B | 10.40B | 9.82B | 8.62B | 8.13B | 6.46B | 5.54B | 4.80B | 4.42B | 3.10B | 3.56B | 3.17B | 2.70B | 2.28B | 1.87B | 1.41B | 1.07B | 857.00M |
| Income Before Tax Ratio | 3.14% | 27.74% | 28.50% | 21.17% | 24.47% | 20.57% | 16.82% | 18.84% | 13.67% | 40.92% | 12.59% | 19.53% | 15.26% | 3.59% | 55.75% | 41.12% | 13.93% | 27.48% | 33.45% | 34.76% | 40.25% | 19.72% | 21.80% | 24.34% | 26.35% | 30.24% | 27.34% | 27.94% | 28.76% | 29.49% | 29.55% | 36.88% | 36.81% | 35.18% | 34.85% | 31.50% | 27.76% | 25.99% | 24.16% |
| Income Tax Expense | 1.51B | 1.92B | 1.52B | 1.71B | 1.69B | 2.51B | 4.16B | 1.79B | 942.00M | 5.35B | 1.03B | 2.44B | 942.00M | 671.00M | 2.27B | 2.00B | 95.30M | 1.79B | 2.73B | 2.16B | 2.46B | 3.06B | 3.12B | 3.00B | 2.73B | 2.88B | 1.85B | 1.66B | 1.46B | 1.42B | 936.50M | 1.12B | 1.05B | 917.60M | 787.60M | 664.20M | 498.80M | 397.60M | 317.10M |
| Net Income | 365.00M | 14.52B | 13.05B | 7.07B | 9.84B | 6.22B | 2.57B | 5.69B | 4.44B | 11.92B | 4.40B | 6.66B | 6.27B | 861.00M | 12.90B | 7.81B | 3.28B | 4.43B | 4.63B | 5.81B | 6.83B | 7.15B | 7.28B | 6.82B | 5.89B | 5.25B | 4.61B | 3.88B | 3.34B | 3.00B | 2.17B | 1.98B | 2.12B | 1.78B | 1.50B | 1.21B | 906.40M | 675.70M | 539.90M |
| Net Income Ratio | 0.61% | 24.49% | 26.79% | 17.02% | 21.01% | 14.71% | 6.40% | 14.30% | 11.25% | 28.22% | 10.00% | 14.09% | 13.05% | 1.87% | 47.04% | 32.74% | 13.54% | 19.59% | 21.04% | 25.34% | 30.38% | 13.80% | 15.26% | 16.90% | 18.01% | 19.51% | 19.52% | 19.57% | 19.99% | 20.02% | 20.63% | 20.54% | 24.66% | 23.22% | 22.83% | 20.32% | 17.91% | 16.37% | 15.22% |
| EPS | 0.14 | 5.73 | 5.16 | 2.79 | 3.84 | 2.40 | 0.95 | 2.07 | 1.60 | 4.20 | 1.50 | 2.20 | 2.06 | 0.28 | 4.15 | 3.65 | -1.04 | 2.04 | 2.11 | 2.63 | 2.97 | 3.17 | 3.18 | 2.96 | 2.51 | 2.21 | 1.92 | 1.60 | 1.35 | 1.19 | 0.94 | 1.06 | 0.92 | 0.76 | 0.63 | 0.51 | 0.37 | 0.27 | 0.21 |
| EPS Diluted | 0.14 | 5.71 | 5.14 | 2.78 | 3.82 | 2.32 | 0.93 | 2.04 | 1.56 | 4.07 | 1.47 | 2.16 | 2.02 | 0.28 | 4.15 | 3.63 | -1.04 | 2.03 | 2.10 | 2.62 | 2.97 | 3.14 | 3.14 | 2.90 | 2.45 | 2.15 | 1.87 | 1.56 | 1.32 | 1.18 | 0.93 | 1.05 | 0.91 | 0.76 | 0.63 | 0.51 | 0.37 | 0.27 | 0.21 |
| Weighted Avg Shares Out | 2.61B | 2.53B | 2.53B | 2.53B | 2.57B | 2.59B | 2.70B | 2.75B | 2.78B | 2.84B | 2.93B | 3.03B | 3.04B | 3.10B | 2.11B | 2.14B | 2.17B | 2.18B | 2.20B | 2.22B | 2.24B | 2.26B | 2.29B | 2.31B | 2.35B | 2.37B | 2.40B | 2.43B | 2.47B | 2.51B | 2.30B | 1.87B | 2.31B | 2.34B | 2.37B | 2.37B | 2.45B | 2.50B | 2.57B |
| Weighted Avg Shares Out (Dil) | 2.55B | 2.54B | 2.54B | 2.54B | 2.58B | 2.68B | 2.75B | 2.79B | 2.84B | 2.93B | 3.00B | 3.08B | 3.09B | 3.12B | 2.27B | 2.14B | 2.19B | 2.19B | 2.20B | 2.23B | 2.25B | 2.28B | 2.32B | 2.35B | 2.40B | 2.44B | 2.47B | 2.49B | 2.54B | 2.55B | 2.33B | 1.89B | 2.33B | 2.34B | 2.37B | 2.37B | 2.45B | 2.50B | 2.57B |
Merck & Co. Inc. (MRK) Citi's 2024 Global Healthcare Conference (Transcript)
Merck & Co. Inc. (NYSE:MRK ) Citi's 2024 Global Healthcare Conference December 5, 2024 8:00 AM ET Company Participants Rob Davis - Chairman and CEO Eliav Barr - Senior VP, Head of Global Clinical Development and CMO Conference Call Participants...
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Tanzania President, Merck Foundation Chairman and CEO With 15 First Ladies Inaugurate Their 11th Africa Asia Luminary 2024
DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #AfricaAsiaLuminary--Merck Foundation, conducted the 11th Edition of their annual conference, “Merck Foundation Africa Asia Luminary”.
Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults
RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study Evaluating LAGEVRIO for the Treatment of COVID-19 in High-Risk Adults.
3 Ultra-Cheap Dividend Stocks to Buy in December
If you're concerned about rising valuations in the stock market or just want some reliable income for your portfolio, now may be an optimal time to load on dividend stocks, many of which are looking incredibly cheap. While growth investors...
Dow 30 December Dogs Show 28 Pay Dividends And 1 "Safer" Buy
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding its single share price. Five more Dow Dogs, including Cisco and Merck, are within 66% of meeting this ideal. Analysts forecast 11.36% to 31.73%...
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC
This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.
3 Dividend Growth Stocks to Buy in December And Hold Forever
Many investors can pigeon hole buying dividend stocks as a particular investment style that may not fit with their long-term goals.
Merck & Co., Inc. (MRK) 7th Annual Evercore ISI HealthCONx Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) 7th Annual Evercore ISI HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Peter Dannenbaum - SVP, IR Eliav Barr - Chief Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Umer...
Top Value Managers Are Buying These 4 Stocks
#Morningstar #TopValueStocks #stockinvesting Here's where some of the best managers are finding new opportunities in today's market. 00:00 Introduction 00:20 Lululemon LULU 00:56 Air Products and Chemicals APD 01:31 Genuine Parts GPC 02:08 Merck MRK I'm Susan Dziubinski with Morningstar.
Source: https://incomestatements.info
Category: Stock Reports